Dapagliflozin in PRESERVED Ejection Fraction Heart Failure (PRESERVED-HF)https://clinicaltrials.gov/ct2/show/NCT03030235?recrs=e&cond=Heart&phase=23&lupd_s=06%2F01%2F2021&lupd_e=01%2F18%2F2022&draw=2&rank=4The major goal of this study is to see how dapagliflozin affects heart failure, disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with retained systolic function when compared to placebo.Description in detail:The impact of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (NTproBNP and BNP), symptoms, health status, and quality of life in patients with chronic heart failure with maintained systolic function in a 12-week randomized, double-blind, placebo-controlled trial. The effects of dapagliflozin vs. placebo on various echocardiographic parameters will also be investigated in an imaging substudy. - Heart Failure and Cardiomyopathies - 652_600c9efaa3c99

Podcast- Dr. Mikhail Kosiborod, MD- Dapagliflozin in PRESERVED Ejection Fraction Heart Failure (PRESERVED-HF) @MkosiborodMD @StLukesHealth #HeartFailure #Cardiology #Research

Podcast- Dr. Mikhail Kosiborod, MD- Dapagliflozin in PRESERVED Ejection Fraction Heart Failure (PRESERVED-HF) @MkosiborodMD @StLukesHealth #HeartFailure #Cardiology #Research

8 months
45 Views
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:

Dapagliflozin in PRESERVED Ejection Fraction Heart Failure (PRESERVED-HF)

https://clinicaltrials.gov/ct2/show/NCT03030235?recrs=e&cond=Heart&phase=23&lupd_s=06%2F01%2F2021&lupd_e=01%2F18%2F2022&draw=2&rank=4

The major goal of this study is to see how dapagliflozin affects heart failure, disease-specific biomarkers, symptoms, health status, and quality of life in patients with chronic heart failure with retained systolic function when compared to placebo.

Description in detail:

The impact of once-daily dapagliflozin 10 mg on heart failure disease-specific biomarkers (NTproBNP and BNP), symptoms, health status, and quality of life in patients with chronic heart failure with maintained systolic function in a 12-week randomized, double-blind, placebo-controlled trial. The effects of dapagliflozin vs. placebo on various echocardiographic parameters will also be investigated in an imaging substudy.

Up Next Autoplay